AstraZeneca drug will get breakthrough status at the begining of cancer of the lung

LONDON (Reuters) – AstraZeneca stated on Monday its immunotherapy drug Imfinzi have been granted “breakthrough” designation by U.S. regulators for the treatment of non-metastatic cancer of the lung, following the prosperity of the so-known as Off-shore trial.

The Fda decision makes way for any fast regulatory review and confirms the drug’s potential in earlier stage disease, despite its initial failure within the key Mystic trial, which targeted the larger advanced cancer market.

Reporting by Ben Hirschler, editing by Louise Heavens

Leave a Reply

Your email address will not be published. Required fields are marked *